Ascelia Pharma AB (publ) Stock Price

OM:ACE Community·SEK 85.1m Market Cap

3 Narratives written by author
0 Comments on narratives written by author
10 Fair Values set on narratives written by author

Author Program NEW Create Narrative

ACE Share Price Performance

SEK 0.64

-3.28 (-83.75%)

SEK 2.40

Fair Value

SEK 0.64

-3.28 (-83.75%)

73.5% undervalued

SEK 2.40

Fair Value

SEK 0.64

SEK 2.40

SEK 3.70

SEK 3.95

Sat, 15 Aug 26

Fair ValueSEK 2.40

Share Pricen/a

ACE Community Narratives

AnalystConsensusTarget's

Fair Value

Fair Value SEK 2.4 73.5% undervalued

Renal Imaging Opportunity Will Support Future Rare Oncology Expansion Narrative

AnalystHighTarget's

Fair Value

Fair Value SEK 3.7 82.8% undervalued

Manganese Contrast Agent Safety Tailwinds Will Support Long Term Upside Potential

AnalystLowTarget's

Fair Value

Fair Value SEK 3.95 83.9% undervalued

Severe Regulatory And Funding Risks Around Cancer Imaging Will Eventually Reward Patient Safety Focus

Ascelia Pharma

73.5% undervalued

Renal Imaging Opportunity Will Support Future Rare Oncology Expansion Narrative

AnalystConsensusTarget

Updated 15 Aug

Read Narrative

Ascelia Pharma

82.8% undervalued

Manganese Contrast Agent Safety Tailwinds Will Support Long Term Upside Potential

AnalystHighTarget

Updated 18 Jul

Read Narrative

Ascelia Pharma

83.9% undervalued

Severe Regulatory And Funding Risks Around Cancer Imaging Will Eventually Reward Patient Safety Focus

AnalystLowTarget

Published 19 Mar

Read Narrative

Trending Discussion

No trending discussion available.

Snowflake Analysis

Reasonable growth potential with adequate balance sheet.

4 Risks

2 Rewards

View Full Analysis

Ascelia Pharma AB (publ) Key Details

Last Reported Earnings

Jun 30, 2026

Next Reporting Earnings

Nov 05, 2026

: -0.45
: 0%
: 0%
: 0%

View Full Analysis

About ACE

Founded: 1999
Employees: 10
CEO: Magnus Corfitzen
WebsiteView website: www.ascelia.com

Ascelia Pharma AB (publ), a biotech company, develops identifies, develops, and commercializes novel drugs to treat orphan oncology treatments in Sweden. It develops Orviglance, a novel non-gadolinium diagnostic drug, which is in Phase 3 clinical trial for use in MRI-scans of the liver; and Oncoral, a novel oral irinotecan chemotherapy tablet, that is in Phase 2 clinical trial for the treatment of gastric cancer. The company has a collaboration agreement with the Taiho Oncology Inc. The company was incorporated in 1999 and is headquartered in Malmö, Sweden.